178 related articles for article (PubMed ID: 34759212)
21. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
[TBL] [Abstract][Full Text] [Related]
22. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
23. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
25. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
[TBL] [Abstract][Full Text] [Related]
26. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
Gupta A; De Jesus-Acosta A; Zheng L; Lee V; Kamel I; Le D; Pishvaian M; Laheru D
Front Oncol; 2023; 13():1250136. PubMed ID: 37700832
[TBL] [Abstract][Full Text] [Related]
28. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
29. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
30. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Frampton JE
Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
[TBL] [Abstract][Full Text] [Related]
31. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
32. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
33. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Kieler M; Unseld M; Bianconi D; Scheithauer W; Prager GW
Ther Adv Med Oncol; 2019; 11():1758835919853196. PubMed ID: 31360237
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
35. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
36. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
Yoo C; Im HS; Kim KP; Oh DY; Lee KH; Chon HJ; Kim JH; Kang M; Kim I; Lee GJ; Oh SY; Choi Y; Choi HJ; Kim ST; Park JO; Ryoo BY
Ther Adv Med Oncol; 2019; 11():1758835919871126. PubMed ID: 31489036
[TBL] [Abstract][Full Text] [Related]
37. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
[TBL] [Abstract][Full Text] [Related]
38. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
39. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.
Kobayashi S; Tezuka S; Yamachika Y; Tsunoda S; Nagashima S; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
BMC Cancer; 2023 Feb; 23(1):177. PubMed ID: 36809997
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
